Meeting
2023 ASCO Genitourinary Cancers Symposium
The Bristol Bladder Trial: Five year outcomes in patients treated with neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder.
Authors
Amarnath Challapalli
Bristol Haematology and Oncology Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
Amarnath Challapalli , Paul White , Susan Masson , Emily Foulstone , Emily Renninson , Alicia Bravo , Sylvia Pearson , Narges Dailami , Raj Persad , Anthony Koupparis , Edward Rowe , Jon Oxley , Julian Kabala , Janice Ash-Miles , Amit Bahl
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Clinical Trial Registration Number
NCT01616875
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 493)
DOI
10.1200/JCO.2023.41.6_suppl.493
Abstract #
493
Poster Bd #
J15
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Pathological response rates and quality of life outcomes of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle-invasive transitional cell carcinoma of the urinary bladder.
First Author: Amarnath Challapalli
Poster
2018 Genitourinary Cancers Symposium
The Bristol Bladder trial: A single-arm phase II trial of cisplatin and cabazitaxel for muscle invasive transitional cell carcinoma of the urinary bladder prior to radical cystectomy.
First Author: Amit Bahl
Poster
2023 ASCO Genitourinary Cancers Symposium
Neoadjuvant cisplatin-based chemotherapy followed by selective bladder preservation chemoradiotherapy (CRT) in muscle-invasive urothelial carcinoma of bladder (MIBC): A combined retrospective analysis of two prospective studies.
First Author: Joohyun Hong
Poster
2022 ASCO Annual Meeting
Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial.
First Author: Nieves Martinez Chanza